The STRAVI study investigates the molecular pathways distinguishing repigmented and non-repigmented lesions in vitiligo during standard combination therapy. Using advanced transcriptomic and serum analysis, this research aims to uncover key factors influencing treatment response. Participants will receive oral mini-pulse methylprednisolone (16 mg twice weekly) combined with Narrowband UVB (Nb-UVB) phototherapy (twice weekly) over 24 weeks. Skin and blood samples will be collected to assess pro-inflammatory cytokines, chemokines, and transcriptomic profiles.

Key Details

• Age Range: 18 to 65 years
• Estimated Enrollment: 10 participants
• Treatment Duration: 24 weeks

Procedures

• Skin Biopsies: One 4mm biopsy from the forearm at baseline; two 4mm biopsies at months 3 and 6 from the same lesion (repigmented and non-responded areas). Samples will undergo same-day single-cell RNA sequencing (scRNA-seq).
• Blood Samples: 30 mL collected at weeks 0, 12, and 24 to measure pro-inflammatory cytokines and chemokines.

For a complete list of inclusion and exclusion criteria, interested individuals should contact the study team or visit the official ClinicalTrials.gov page (NCT05927272). Only the research staff can determine if a person fully qualifies for the study.

The VRF will continue to monitor the progress of this trial and provide updates as they become available. We encourage eligible individuals to consider participating in this important research effort to advance vitiligo treatment.